Bibliographic record
Abstract
Osteoporosis is a major public health issue affecting a large proportion of the population over 50 years old. It is characterized by compromised bone strength, which primarily reflects both low bone mass and microarchitectural deterioration of bone tissue favouring the occurrence of fragility fractures. It is often a progressive and debilitating disease, which leads to a huge societal burden through the increased morbidity, mortality, and cost associated with these fractures. Vertebral fractures are the most frequent fragility fractures and cause significant pain, vertebral deformity, and long-term disability. Hip fracture is the most devastating consequence of osteoporosis and invariably requires hospitalization. As life expectancy increases, so does the presence of chronic diseases such as osteoporosis. It is thus particularly important to manage this condition, which will affect more people and for longer. The aim of management is therefore to reduce the risk of future fractures, and a number of anti-osteoporotic treatments have been developed to treat patients with postmenopausal osteoporosis. Some currently available anti-osteoporosis agents act by inhibiting bone resorption, but they also decrease bone formation, thereby suppressing bone turnover. Some others act by stimulating bone formation, but they also increase bone resorption. In contrast, strontium ranelate is the only anti-osteoporosis treatment with a dual mode of action, simultaneously increasing bone formation and decreasing bone resorption, thus rebalancing bone turnover in favour of bone formation. As a result of its unique dual mode of action optimizing bone turnover, strontium ranelate produces new, well-mineralized bone of good quality. These symposium proceedings will provide an update of studies enhancing our understanding of the tissue and cellular mode of action of strontium ranelate. Moreover, the evidence-based clinical trial data, which make it a new first-line treatment for postmenopausal osteoporosis whatever the severity of the disease, even in the elderly, will be presented. The clinical benefits for patients will also be reviewed, including improvements in various aspects of the quality of life. We thus have a new and effective agent, with a different, novel mechanism of action, to use in the ongoing battle against osteoporosis and fractures.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.002 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.001 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.002 | 0.004 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; both teacher heads agree on what is shown here.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".